

**20<sup>th</sup> ANNUAL  
CARDIOMETABOLIC  
HEALTH CONGRESS**



**APPLYING  
CLINICAL  
PEARLS TO  
PRACTICE**

## Disclosures

### Planners and Managers

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies.  
The CMHC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

### Faculty

**Abushamat:**

**Consultant, Advisor, Speaker:** New Amsterdam, Novartis, Opus Medicus

**Aggarwal:**

**Consultant, Advisor, Speaker:** Lexicon, Amarin

**Researcher:** Novartis, Bristol Myers Squibb-Pfizer alliance, Cleerly

**Akinboboye:**

**Consultant, Advisor, Speaker:** Alnylam Pharmaceuticals, Astra Zeneca, Bridgebio, Pfizer Inc.

**Al-Aly:**

Dr. Al-Aly has no relevant financial relationship(s) with ineligible companies to disclose.

**Ballantyne:**

**Grant/Research Support-** All significant. (All paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Arrowhead, Ionis, Eli Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche Diagnostic, NIH, AHA, ADA.

**Consultant-** 89Bio, Abbott Diagnostics, Amgen, Arrowhead, Astra Zeneca, Denka Seiken\*, Esperion, Genentech, Ionis, Eli Lilly\*, Merck\*, New Amsterdam, Novartis\*, Novo Nordisk, Roche Diagnostic

\*Significant where noted (>\$5,000); remainder modest (<\$5,000).

**Barb:**

**Consultant, Advisor, Speaker:** Boehringer Ingelheim, Novo Nordisk

**Researcher:** Boehringer Ingelheim, Inventiva

**Bene-Alhasan:**

Dr. Bene-Alhasan has no relevant financial relationship(s) with ineligible companies to disclose.

**Bhatt:**

**Researcher:** Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio; Royalties: Elsevier (Editor, Braunwald's Heart Disease)

**Consultant, Advisor, Speaker:** Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, E-Star Biotech, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, NirvaMed, Novo Nordisk, Stasys, Tourmaline Bio

**Consultant, Advisor, Speaker:** Consultant: Broadview Ventures, Corcept Therapeutics, GlaxoSmithKline, Hims, SFJ, Summa Therapeutics, Youngene

**Individual publicly traded stocks and stock options:** Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock)

**Other:** Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock)

**Other:** Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee)

**Other:** Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute, Rutgers University (for the NIH-funded MINT Trial)

**Royalties or Patent Beneficiary:** Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent)

**Other:** Site Co-Investigator: Cleerly

**Bozkurt:**

**Consultant, Advisor, Speaker:** ABIOMED / Johnson and Johnson, Bayer, Boehringer Ingelheim, Cardurion, Cytokinetics, Eli Lilly, Medtronic, Merck, Idorsia, Novo Nordisk, Regeneron, Renovacor, Roche, Salubris, Sanofi-Aventis, scPharmaceuticals, Vifor, Respicardia/ Zoll

**Dinani:**

**Consultant, Advisor, Speaker:** Madrigal Pharmaceuticals, Novo Nordisk, Petauri

**Other:** Akero, 89Bio, Inventiva, NIH/NCI

**Eckel:**

Dr. Eckel has no relevant financial relationship(s) with ineligible companies to disclose.

**Ferdinand:**

**Consultant, Advisor, Speaker:** Amgen, Novartis, Boehringer Ingelheim, Medtronic, AstraZeneca

**Fisher:**

**Researcher:** Recor Medical

**Consultant, Advisor, Speaker:** Recor Medical, Alnylam, Astra Zeneca, Aktiia

**Fitzpatrick:**

Ms. Fitzpatrick has no relevant financial relationship(s) with ineligible companies to disclose.

**Green:**

**Consultant, Advisor, Speaker:** AstraZeneca, Bayer, Boehringer Ingelheim, Corcept, Vertex, Valo, Lilly, Mineralys, Novo Nordisk, Idorsia, Zealand

**Researcher:** Boehringer Ingelheim, Lilly, Merck, Roche, Bluedrop

**Kaminsky:**

Dr. Kaminsky has no relevant financial relationship(s) with ineligible companies to disclose.

**Kruger:**

Dr. Kruger reports grants from Henry Ford Health System , during the conduct of the study; grants and personal fees from Novo Nordisk, personal fees from Jansen , grants and personal fees from Eli Lilly , personal fees from BI, personal fees from Sanofi, grants, personal fees and other from Dexcom, grants and personal fees from Abbott , personal fees from Intarsia , personal fees from AZ, outside the submitted work.

**Michos:**

**Consultant, Advisor, Speaker:** Boehringer Ingelheim, Bayer, Arrowhead, Ionis, New Amsterdam, Merck, Novo Nordisk, Eli Lilly

**Consultant:** Medtronic, Edwards Lifescience, Esperion, AstraZeneca, Pfizer, Zoll, Amgen

**Miller:**

**Consultant, Advisor, Speaker:** Abbott, Bayer, Corcept, Eli Lilly/BI, Insulet, Novo Nordisk

**Moriarty:**

**Research, Consultant:** Regeneron, Amgen, Esperion, Kaneka

**Research, Advisory Board:** Novartis

**Research:** Ionis, FH Foundation, Aegerion, Merck, Arrowhead

**Morris:**

Dr. Morris has no relevant financial relationship(s) with ineligible companies to disclose.

**Natarajan:**

**Researcher:** Allelica, Amgen, Apple, Boston Scientific, Genentech/Roche, Novartis

**Consultant, Advisor, Speaker:** Allelica, Apple, AstraZeneca, Bain Capital, Blackstone Life Sciences, Bristol Myers Squibb, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, Genentech/Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, Novo Nordisk, TenSixteen Bio, Tourmaline Bio

**Other: Equity:** Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli, TenSixteen Bio

**Other: Spousal Employment:** Vertex Pharmaceuticals

**Ndumele:**

Dr. Ndumele has no relevant financial relationship(s) with ineligible companies to disclose.

**Peters:**

**Consultant, Advisor, Speaker:** Vertex, Medscape

**Researcher:** Insulet, Abbott Diabetes Care, Zucara

**Individual publicly traded stocks and stock options:** Omada Health

**Ridker:**

PMR has received institutional research grant support from Kowa, Novartis, Amarin, Pfizer, Esperion, NovoNordisk, and the NHLBI; during the past 5 years has served as a consultant to Novartis, Flame, Agepha, Ardelyx, Arrowhead, AstraZeneca, CSL Behring, Janssen, Civi Biopharm, Glaxo Smith Kline, SOCAR, Novo Nordisk, Health Outlook, Montai Health, Eli Lilly, New Amsterdam, Boehringer-Ingelheim, RTI; Zomagen, Cytokinetics, Horizon Therapeutics, and Cardio Therapeutics; has minority shareholder equity positions in Uppton, Bitterroot Bio, and Angiowave; and receives compensation for service on the Peter Munk Advisory Board (University of Toronto), the Leducq Foundation, Paris FR, and the Baim Institute (Boston, MA).

**Rosas:**

**Researcher:** Bayer, AstraZeneca, Prokidney

**Consultant, Advisor, Speaker:** Travere

**Independent Contractor:** Dynamed

**Robinson A.**

Mr. Robinson has no relevant financial relationship(s) with ineligible companies to disclose.

**Robinson D.**

Ms. Robinson has no relevant financial relationship(s) with ineligible companies to disclose.

**Ruberg:**

**Researcher:** BridgeBio Pharm, TriNetX/AstraZeneca, Anumana, Pfizer

**Consultant, Advisor, Speaker:** eMyosound, Attralus

**Ryan:**

**Consultant, Advisor, Speaker:** Abbvie, Altimune, Amgen, AstraZeneca, Biohaven, Boehringer Ingelheim, Calibrate, Carmot/Roche/Genentech, Currax, CinRx, Epitomee, Nestle, Novo Nordisk, Pfizer, PPD, Regeneron, Structure Therapeutics, Source Bio, Tenvie, Wondr Health, Zealand

**Smith:**

**Consultant, Advisor, Speaker:** Argenx, UCB, Sangamo, Seismic, Merz, Lilly

**Other:** Eidos

**Stanton:**

Dr. Stanton has no relevant financial relationship(s) with ineligible companies to disclose.

**Taub:**

**Consultant, Advisor, Speaker:** Amgen, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Medtronic Clearly, Esperion, Edwards, Lexicon, Jazz Pharma, Merck, Roche

**Tu:**

**Speaker, Advisory Board:** Sanofi

**Speaker:** Abbott, Intuity Medical, Astra Zeneca

**Advisory Board:** Novo Nordisk, Insulet, Eli Lilly

**Publication Support:** Bayer

**Unlu:**

**Consultant, Advisor, Speaker:** AlwithCare, Curevium

**Weir:**

**Scientific Advisor:** AstraZeneca, Bayer, CSL Vifor, Novo Nordisk, Vera, Mineralys